TNFRSF17 and plasma cell myeloma: Due to the observed variance in treatment responses between patient groups with BCMA-expressing myeloma cells and those without, it is important to conduct more studies, including larger cohorts of patients, to reach a definite conclusion on whether BCMA has a role in treatment efficacy.